(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoic acid
• 化学式: C₁₈H₂₈O₂
• 分子量: 276.4
• InChiKey: JIWBIWFOSCKQMA-GFRMADBLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  20
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoic acid 、 甲醇 生成 octadeca-6c,9c,12c,15c-tetraenoic acid methyl ester
  参考文献：
  名称：

  REZANKA, T., LC AND GC , 8,(1990) N, C. 542, 544-545

  摘要：

  DOI：
• 作为产物：
  描述：

  尿素 生成 (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoic acid
  参考文献：
  名称：

  TRAITLER, HELMUT;STUDER, ALFRED

  摘要：

  DOI：

文献信息

• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。
• BIOPASSIVATING MEMBRANE STABILIZATION BY MEANS OF NITROCARBOXYLIC ACID-CONTAINING PHOSPHOLIPIDS IN PREPARATIONS AND COATINGS
  申请人：Dietz Ulrich

  公开号：US20140099354A1

  公开（公告）日：2014-04-10

  The present invention relates to nitro-carboxylic acid (s)-containing phospholipids, to be used for coating of medical devices such as stents, catheter balloons, wound pads or surgical suture material and for bio-passivating compositions, such as rinses, waterproofing solutions, coating solutions, cryoprotection solutions, cold preservation media, lyoprotection solutions, contrast media solutions, preservation and reperfusion solutions containing these compounds as well as preparing solutions thereof and coating medical devices as well as their uses.

  本发明涉及一种含硝基羧酸（s）的磷脂，用于涂覆医疗器械，如支架、导管球囊、伤口垫或外科缝合材料，以及用于生物钝化组合物，如漱口液、防水溶液、涂层溶液、冷冻保护溶液、冷藏介质、冻干保护溶液、造影介质溶液、含有这些化合物的保存和再灌注溶液，以及制备这些溶液和涂覆医疗器械以及它们的用途。
• [EN] SMALL MOLECULE COMPOUNDS TO SUPPORT HEALTHY HUMAN AGING<br/>[FR] COMPOSÉS À PETITES MOLÉCULES POUR FAVORISER UN VIEILLISSEMENT HUMAIN SAIN
  申请人：CARDAX PHARMA INC

  公开号：WO2018183353A1

  公开（公告）日：2018-10-04

  Disclosed herein are methods of activating expression of the FOXO3 gene in a subject comprising administering to a subject small molecule compound (such as astaxanthin and/or one or more astaxanthin derivatives), or pharmaceutically acceptable salts thereof, in an amount sufficient to at least partially increase the amount of FoxO3 expressed in the subject.

  本文揭示了一种激活主体中FOXO3基因表达的方法，包括向主体施用小分子化合物（如虾青素和/或一个或多个虾青素衍生物）或其药用可接受盐，以足够数量至少部分增加主体中表达的FoxO3的方法。
• [EN] FATTY ACID CYSTEAMINE CONJUGATES OF CFTR MODULATORS AND THEIR USE IN TREATING MEDICAL DISORDERS<br/>[FR] CONJUGUÉS DE CYSTÉAMINE D'ACIDE GRAS DE MODULATEURS DE CFTR ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：CATABASIS PHARMACEUTICALS INC

  公开号：WO2016086136A1

  公开（公告）日：2016-06-02

  The invention relates to fatty acid cysteamine conjugates of a CFTR modulator, compositions comprising a fatty acid cysteamine conjugate of a CFTR modulator, and methods for using such conjugates and compositions to treat disease, such as a disease caused by dysregulation of autophagy.

  这项发明涉及一种CFTR调节剂的脂肪酸半胱氨酸共轭物，包括CFTR调节剂的脂肪酸半胱氨酸共轭物的组合物，以及使用这种共轭物和组合物治疗疾病的方法，例如由自噬失调引起的疾病。